KalVista Pharmaceuticals, Inc. announces the publication of new data in Clinical & Experimental Allergy characterizing KVD900, a novel, potent and selective oral inhibitor of plasma kallikrein, a critical mediator of attacks in patients with HAE. In this new publication, orally administered KVD900 was shown to be quickly absorbed and provided rapid and near-complete inhibition of plasma kallikrein and strong suppression of kallikrein-kinin system activation in patients with HAE.
“Based on these results, on-demand administration of KVD900 is further demonstrated to block the generation of plasma kallikrein and bradykinin in HAE patient plasma and thereby may provide an opportunity to halt and reverse HAE attacks,” says Andrew Crockett, CEO of KalVista. “These data provide the underlying basis for the clinical results we reported for our phase 2 trial of KVD900 in on-demand treatment of HAE attacks, and further support our ongoing phase 3 Konfident trial for KVD900 in the same indication.”
(Source: KalVista)
